



## Insurance Tracker

### Individual WRP for private players grows 14.2% YoY in Jan'23

LIC's WRP rises 3.0% YoY; market share for private players moderates to 64%

- The Individual Weighted Received Premium (WRP) for private players grew 14.2% YoY in Jan'23 (at a three-year CAGR of 9.3%, up 15.9% in Dec'22). The same for industry grew 9.9% YoY in Jan'23 (at a three-year CAGR of -2.8%, up 11.9% in Dec'22). Over Apr-Jan'23, private players' WRP grew 18.0% YoY (at a three-year CAGR of 12.7%).
- Among listed players, HDFCLIFE (including Exide merger) reported a 27.3% YoY growth in Jan'23 (at a three-year CAGR of 17.4%). MAXLIFE/SBILIFE reported modest growth of 8.6%/7.5% YoY (at a three-year CAGR of -1.5%/5.4%). IPRU reported weak trends with a growth of 1.4% YoY (at a three-year CAGR of -4.5%).
- Among mid-sized players, Kotak Life/Tata AIA/Bajaj Allianz/Birla Sun Life reported a growth of 38%/36%/26%/8% YoY (at a three-year CAGR of 16%/27%/31%/8%), respectively.
- LIC posted a 3.0% YoY growth in Individual WRP (at a three-year CAGR of -15.6%, up 3.1% in Dec'22). Over Apr-Jan'23, Individual WRP for LIC grew 10.7% YoY (at a three-year CAGR of -1.2%).
- After reporting a modest growth over Jul-Oct'22, the industry is witnessing a pick up over the past few months with growth reverting to double digits. While the demand for Annuity and Non-PAR policies has been healthy, we remain watchful of the medium-term growth as taxability of receipts kicks in from 1<sup>st</sup> Apr'23. Protection on the other hand is witnessing healthy recovery. We prefer SBILIFE.

#### Individual WRP and YoY growth (%)

Individual WRP, INR m	Jan'23	YoY growth		
<b>Grand total</b>	86,634	9.9%		
Total Public	31,175	3.0%		
Total Private	55,459	14.2%		
SBILIFE	13,905	7.5%		
HDFCLIFE	9,223	27.3%		
Tata AIA	5,442	35.8%		
IPRU	5,418	1.4%		
Bajaj Allianz	4,127	25.6%		
MAXLIFE	3,999	8.6%		
Kotak Life	2,521	37.9%		
PNB MetLife	2,051	20.0%		
Birla Sun Life	1,961	8.0%		

Source: IRDAI, LIC Council, MOFSL

# On an Individual WRP basis, the market share for private players contracts to ~64% in Jan'23

In terms of Individual WRP, the market share for private players contracted 740bp MoM to 64.0% in Jan'23. LIC's market share improved to 36%. SBILIFE (16.6%) remained the largest private insurer in terms of Individual WRP over Apr-Jan'23, followed by HDFCLIFE (9.8%) and IPRU (6.1%). On an unweighted basis too, SBILIFE was the largest private insurer, with a market share of 8.1%, followed by HDFCLIFE (7.0%) and IPRU (4.3%).

#### Performance of key private players

On an Individual WRP basis, the combined market share of listed players – SBILIFE, HDFCLIFE, MAXLIFE, and IPRU – stood at 58% of all private players in Apr-Jan'23. Among large private insurers, on an Individual WRP basis, Tata AIA has surpassed MAXLIFE to emerge as the fourth largest, while Bajaj Allianz and Birla Sun life remained firmly positioned at the sixth and seventh spots. Among key listed players on the basis of Individual WRP –

- **HDFCLIFE** (including Exide merger) reported a growth of 27.3% YoY (up 17.9% in Apr-Jan'23). Total unweighted premium rose 25.5% YoY (up 9.1% in Apr-Jan'23).
- **SBILIFE** reported a growth of 7.5% YoY (up 20.9% in Apr-Jan'23). Total unweighted premium grew 31.9% YoY (up 16.1% in Apr-Jan'23).
- **IPRU** reported a growth of 1.4% YoY (-3.6% in Apr-Jan'23). Total unweighted premium grew 14.5% YoY (up 10.6% in Apr-Jan'23).
- MAXLIFE reported a growth of 8.6% YoY (-0.6% in Apr-Jan'23). Total unweighted premium grew 14.5% YoY (up 7.4% in Apr-Jan'23).

Nitin Aggarwal - Research Analyst (Nitin.Aggarwal@MotilalOswal.com)

Research Analyst: Yash Agarwal (Yash.Agarwal@motilaloswal.com)





Exhibit 1: Unweighted new business premium and growth

INR m	Jan'23	YoY growth	Apr-Jan'23	YoY growth	FY22	YoY growth
<b>Grand Total</b>	264,237	20.3%	2,956,136	30.1%	3,142,623	12.9%
Total Public	153,017	18.3%	1,913,034	37.7%	1,987,598	7.9%
Total Private	111,220	23.3%	1,043,102	18.2%	1,155,025	22.7%
SBILIFE	25,722	31.9%	240,824	16.1%	254,582	23.4%
HDFCLIFE	23,501	25.5%	207,987	9.1%	243,011	20.1%
IPRU	14,392	14.5%	127,266	10.6%	150,355	15.4%
Kotak Life	7,833	53.3%	54,882	30.7%	61,427	21.5%
Bajaj Allianz	6,900	0.9%	81,310	23.5%	91,358	15.8%
Tata AIA	6,712	30.1%	57,837	51.4%	53,587	44.7%
MAXLIFE	6,065	14.5%	62,460	7.4%	79,044	29.3%
Birla Sun Life	5,854	45.5%	58,288	38.4%	56,653	16.9%
PNB MetLife	2,950	27.9%	24,131	36.8%	24,679	24.1%

Exhibit 2: Individual WRP, growth, and market share

INR m	Jan'23	YoY growth	Market share	Three-year CAGR	Apr-Jan'23	YoY growth	Market share	FY22	YoY growth	Market share
<b>Grand Total</b>	86,634	9.9%	100.0%	-2.8%	753,078	15.4%	100.0%	875,731	15.7%	100.0%
<b>Total Private</b>	55,459	14.2%	64.0%	9.3%	488,995	18.0%	64.9%	550,769	21.9%	62.9%
<b>Total Public</b>	31,175	3.0%	36.0%	-15.6%	264,084	10.7%	35.1%	324,963	6.7%	37.1%
SBILIFE	13,905	7.5%	16.1%	5.4%	125,299	20.9%	16.6%	128,726	25.9%	14.7%
HDFCLIFE	9,223	27.3%	10.6%	17.4%	74,153	17.9%	9.8%	81,479	16.4%	9.3%
Tata AIA	5,442	35.8%	6.3%	26.6%	47,413	48.8%	6.3%	44,550	30.4%	5.1%
IPRU	5,418	1.4%	6.3%	-4.5%	45,899	-3.6%	6.1%	62,987	15.5%	7.2%
Bajaj Allianz	4,127	25.6%	4.8%	31.0%	36,346	36.2%	4.8%	36,855	49.4%	4.2%
MAXLIFE	3,999	8.6%	4.6%	-1.5%	39,957	-0.6%	5.3%	54,414	11.7%	6.2%
Kotak Life	2,521	37.9%	2.9%	16.2%	16,925	23.4%	2.2%	21,128	16.2%	2.4%
PNB MetLife	2,051	20.0%	2.4%	17.5%	15,745	28.7%	2.1%	17,596	21.2%	2.0%
Birla Sun Life	1,961	8.0%	2.3%	8.1%	20,203	23.5%	2.7%	22,116	14.1%	2.5%

Source: IRDAI, LIC Council, MOFSL

Exhibit 3: Market share among private players based on Unweighted and Individual WRP

INR m	Unw	eighted premiums			Individual WRP	
(%)	Jan'23	Apr-Jan'23	FY22	Jan'23	FY22	
Grand Total	264,237	2,956,136	3,142,623	86,634	753,078	875,731
Total Private	111,220	1,043,102	1,155,025	55,459	488,995	550,769
SBILIFE	23.1%	23.1%	22.0%	25.1%	25.6%	23.4%
HDFCLIFE	21.1%	19.9%	21.0%	16.6%	15.2%	14.8%
IPRU	12.9%	12.2%	13.0%	9.8%	9.4%	11.4%
Kotak Life	7.0%	5.3%	5.3%	4.5%	3.5%	3.8%
Bajaj Allianz	6.2%	7.8%	7.9%	7.4%	7.4%	6.7%
Tata AIA	6.0%	5.5%	4.6%	9.8%	9.7%	8.1%
MAXLIFE	5.5%	6.0%	6.8%	7.2%	8.2%	9.9%
Birla Sun Life	5.3%	5.6%	4.9%	3.5%	4.1%	4.0%
PNB MetLife	2.7%	2.3%	2.1%	3.7%	3.2%	3.2%
Star Union	2.0%	2.5%	1.7%	1.8%	2.1%	1.9%

Source: IRDAI, LIC Council, MOFSL





Exhibit 4: Share of single premium policies increased in Jan'23, indicating improving growth for Annuity or lump sum pay out products

<del></del>															
	FY17	FY18	FY19	FY20	FY21	FY22	Apr- Jan'23	Jun'22	Jul'22	Aug'22	Sep'22	Oct'22	Nov'22	Dec'22	Jan'23
Bajaj Allianz	39%	61%	60%	60%	58%	55%	49%	71%	58%	42%	38%	38%	46%	32%	37%
Reliance Life	9%	5%	3%	5%	5%	3%	3%	2%	4%	2%	3%	2%	3%	2%	2%
SBILIFE	39%	26%	34%	41%	50%	49%	48%	64%	56%	57%	48%	44%	45%	34%	47%
Tata AIA	0%	0%	7%	15%	15%	13%	15%	15%	15%	12%	16%	17%	15%	14%	18%
HDFCLIFE	59%	58%	66%	65%	66%	67%	64%	67%	65%	61%	65%	69%	67%	55%	60%
IPRU	19%	15%	24%	29%	38%	42%	43%	51%	39%	40%	44%	50%	42%	42%	39%
Birla Sun Life	3%	53%	54%	51%	55%	58%	62%	51%	60%	63%	75%	62%	58%	46%	59%
Kotak Life	27%	32%	36%	39%	43%	48%	56%	52%	62%	54%	55%	57%	56%	55%	48%
MAXLIFE	28%	27%	25%	27%	29%	33%	38%	40%	41%	42%	40%	38%	36%	34%	36%
<b>Total Private</b>	35%	35%	40%	42%	47%	47%	48%	54%	49%	48%	48%	49%	47%	43%	44%
LIC	79%	79%	78%	68%	82%	82%	85%	86%	90%	86%	87%	81%	87%	70%	79%
<b>Grand total</b>	66%	66%	65%	60%	70%	69%	72%	75%	79%	73%	75%	70%	74%	55%	64%

Exhibit 5: Market share among players in the Group business

(%)	· ·	Unweighted premium	ıs	Group WRP				
	Jan'23	Apr-Jan'23	FY22	Jan'23	Apr-Jan'23	FY22		
LIC	71.4%	78.1%	76.2%	53.5%	64.2%	64.5%		
Total Private	28.6%	21.9%	23.8%	46.5%	35.8%	35.5%		
HDFCLIFE	8.0%	5.5%	6.7%	6.7%	4.7%	5.1%		
IPRU	5.2%	3.3%	3.0%	16.2%	10.8%	9.5%		
SBILIFE	4.3%	3.7%	4.7%	4.2%	3.7%	4.2%		
Kotak Life	2.9%	1.5%	1.5%	7.8%	3.5%	4.3%		
Birla Sun Life	2.5%	1.8%	1.7%	3.1%	1.8%	1.6%		
Bajaj Allianz	1.7%	2.2%	2.7%	1.9%	3.0%	2.9%		
Star Union	0.8%	0.8%	0.4%	1.3%	2.9%	1.8%		
PNB Met Life	0.5%	0.4%	0.3%	0.8%	0.6%	0.6%		
MAXLIFE	0.5%	0.3%	0.4%	0.4%	0.4%	0.4%		
India First Life	0.4%	0.4%	0.6%	0.2%	0.3%	0.4%		

Source: IRDAI, LIC Council, MOFSL





Exhibit 6: Trend in average policy ticket size (Individual Non-Single segment) – Ticket size increases 20% YoY in Jan'23

INR	FY18	FY19	FY20	FY21	FY22	Jan'23	YoY growth	Apr-Jan'23	YoY growth
Bajaj Allianz	45,448	56,128	61,716	57,782	77,634	74,454	3%	78,234	4%
Exide Life	31,934	33,225	35,057	39,502	56,055	NA	NA	NA	NA
Reliance Life	33,636	38,892	43,677	47,493	60,851	71,303	3%	62,103	5%
SBILIFE	54,929	58,977	63,293	62,033	68,213	76,397	5%	71,507	1%
Tata AIA	62,781	63,712	55,740	73,557	83,624	102,352	23%	95,816	18%
HDFCLIFE	45,244	49,774	66,213	70,782	89,340	101,825	4%	101,906	15%
IPRU	93,116	81,902	87,093	81,918	96,554	111,123	15%	102,024	9%
Birla Sun Life	42,518	59,852	65,309	75,304	98,164	103,474	6%	112,320	18%
Aviva Life	70,440	64,856	59,093	72,183	80,096	76,609	-15%	68,856	-16%
Kotak Life	55,909	55,502	57,929	57,220	69,433	95,756	30%	77,813	19%
MAXLIFE	55,836	58,749	66,634	73,855	86,662	85,588	12%	90,812	6%
PNB MetLife	55,665	64,853	66,865	58,546	68,386	79,465	0%	70,676	12%
Shriram Life	17,382	16,617	16,755	17,408	19,707	22,339	19%	21,207	7%
Bharti AXA Life	40,696	39,234	30,017	51,393	60,579	61,494	13%	69,116	20%
Future Generali	35,301	52,660	56,435	66,421	81,028	93,818	15%	74,018	1%
IDBI Federal Life	40,836	45,328	62,455	74,843	93,573	109,198	0%	102,607	11%
Canara HSBC OBC	78,115	70,659	64,491	56,927	76,324	94,383	13%	81,194	10%
Aegon Religare	24,278	24,238	31,686	23,434	14,099	5,473	-61%	7,080	-51%
Pramerica	37,980	41,574	39,923	39,103	39,683	50,536	0%	45,024	6%
Star Union Dai-ichi	50,941	59,080	71,746	69,925	79,885	72,296	-7%	69,061	-13%
India First Life	38,586	44,873	49,240	45,396	50,729	50,460	-1%	53,701	8%
Edelweiss Tokio	40,852	45,278	42,692	54,303	70,863	81,693	24%	81,721	26%
<b>Total Private</b>	53,476	56,383	60,934	63,228	75,155	84,221	9%	79,914	7%
LIC	12,510	13,128	13,904	13,799	14,484	16,143	17%	17,481	12%
Grand total	22,600	24,214	25,322	26,527	29,968	34,031	20%	36,048	13%





Exhibit 7: Number of policies (Individual Non-Single segment) issued grew 4% YoY for private players in Jan'23

Numbers in '000	FY17	FY18	FY19	FY20	FY21	FY22	Jan'23	YoY growth	Apr-Jan'23	YoY growth
Bajaj Allianz	271	306	309	311	426	471	55	21%	459	31%
Exide Life	188	185	199	188	147	126	NA	NA	NA	NA
Reliance Life	271	216	225	203	189	154	11	-13%	120	-2%
SBILIFE	1,248	1,405	1,506	1,518	1,607	1,828	174	1%	1,680	19%
Tata AIA	183	222	348	475	456	525	52	10%	487	26%
HDFCLIFE	844	1,021	948	858	940	868	87	24%	695	3%
IPRU	670	790	852	747	633	618	47	-10%	430	-10%
Birla Sun Life	301	247	281	259	255	223	19	1%	176	4%
Aviva Life	26	27	26	19	21	24	3	66%	20	32%
Kotak Life	249	274	291	270	296	285	25	7%	204	4%
MAXLIFE	502	560	644	595	639	607	45	-3%	420	-7%
PNB MetLife	216	219	211	194	246	255	26	20%	221	15%
Shriram Life	196	245	273	273	294	263	19	-5%	213	14%
Bharti AXA Life	99	107	147	196	109	117	8	-20%	78	-13%
Future Generali	40	79	71	65	53	39	3	3%	31	11%
IDBI Federal Life	108	102	94	43	36	39	4	11%	33	11%
Canara HSBC OBC	91	105	129	149	176	175	14	-3%	134	6%
Aegon Religare	39	54	42	22	15	7	0	-30%	1	-85%
Pramerica	62	83	71	39	29	29	3	30%	27	23%
Star Union Dai-ichi	118	111	95	76	96	126	14	43%	150	55%
India First Life	125	148	151	172	196	263	26	24%	245	23%
Edelweiss Tokio	41	61	75	75	74	59	4	-9%	37	-16%
<b>Total Private</b>	5,899	6,568	6,987	6,747	6,933	7,101	639	4%	5,923	10%
LIC	18,927	20,098	20,276	21,045	19,990	20,724	1,792	-13%	13,994	0%
<b>Grand total</b>	24,826	26,665	27,264	27,792	26,922	27,825	2,430	-9%	19,918	2%





Exhibit 8: Total number of agents – Mixed trends across insurers; overall industry witnesses an increase

In '000s	FY18	FY19	FY20	FY21	FY22	Jan'23	YoY growth	MoM growth
Bajaj Allianz	70.8	72.7	80.5	88.1	96.1	119.1	28.5%	1.2%
Exide Life	46.1	49.8	44.4	36.9	37.1	NA	NA	NA
Reliance Life	65.1	55.5	63.0	42.6	46.5	53.1	18.8%	0.5%
SBILIFE	108.3	123.6	130.4	170.1	146.1	198.2	47.6%	2.3%
Tata AIA	27.0	29.5	30.9	50.4	55.2	74.8	60.1%	5.5%
HDFCLIFE	77.0	91.2	107.7	112.0	115.4	165.7	43.6%	4.7%
IPRU	151.6	170.6	190.9	187.6	198.9	201.7	1.7%	-0.1%
Birla Sun Life	91.7	81.5	86.0	94.8	79.9	60.9	-20.5%	2.9%
Aviva Life	16.4	13.8	11.3	7.0	5.1	3.6	-33.4%	-4.8%
Kotak Life	94.7	124.5	124.7	109.3	110.7	107.4	-3.9%	3.3%
MAXLIFE	57.0	50.9	46.0	55.2	61.1	70.0	28.5%	-0.4%
PNB MetLife	6.5	7.3	8.8	9.9	12.8	18.4	52.8%	1.9%
Sahara Life	10.5	10.4	10.4	10.4	10.3	10.3	-0.8%	-0.1%
Shriram Life	4.5	4.5	4.4	3.8	3.8	3.7	-2.4%	0.0%
Bharti AXA Life	28.6	39.4	43.3	33.2	37.6	41.8	12.3%	2.2%
Future Generali	11.9	7.6	3.9	2.9	6.2	8.5	56.4%	1.4%
IDBI Federal Life	10.8	14.4	10.6	11.7	13.0	8.8	-31.2%	1.4%
Canara HSBC OBC	-	-	0.1	0.2	0.2	0.1	-26.0%	-0.8%
Aegon Religare	5.7	5.7	1.7	0.4	0.2	0.2	-17.3%	0.0%
DLF Pramerica	12.3	14.3	15.4	14.9	14.3	14.8	2.9%	0.2%
Star Union Dai-ichi	4.8	2.7	1.0	0.3	0.2	0.3	118.7%	13.9%
India First Life	1.7	2.0	2.5	1.9	1.9	1.8	-2.0%	1.2%
Edelweiss Tokio	31.0	43.7	51.7	57.8	63.5	67.5	9.4%	1.0%
Private total	933.9	1,015.5	1,069.6	1,101.3	1,116.2	1,230.6	14.6%	2.0%
LIC	1,148.8	1,179.2	1,208.8	1,353.8	1,326.4	1,326.7	-0.1%	0.3%
Grand total	2,082.7	2,194.7	2,278.5	2,455.1	2,442.6	2,557.3	6.4%	1.1%





Explanation of Investment Rating	
Investment Rating	Expected return (over 12-month)
BUY	>=15%
SELL	< - 10%
NEUTRAL	> - 10 % to 15%
UNDER REVIEW	Rating may undergo a change
NOT RATED	We have forward looking estimates for the stock but we refrain from assigning recommendation

\*In case the recommendation given by the Research Analyst is inconsistent with the investment rating legend for a continuous period of 30 days, the Research Analyst shall within following 30 days take appropriate measures to make the recommendation consistent with the investment rating legend.

#### Disclosures

The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations).

Motilal Oswal Financial Services Ltd. (MOFSL) is a SEBI Registered Research Analyst having registration no. INH000000412. MOFSL, the Research Entity (RE) as defined in the Regulations, is engaged in the business of providing Stock broking services, Depository participant services & distribution of various financial products. MOFSL is a listed public company, the details in respect of which are available on <a href="https://www.motilaloswal.com">www.motilaloswal.com</a>. MOFSL (erstwhile Motilal Oswal Securities Limited - MOSL) is registered with the Securities & Exchange Board of India (SEBI) and is a registered Trading Member with National Stock Exchange of India Ltd. (NSE) and Bombay Stock Exchange Limited (BSE), Multi Commodity Exchange of India Limited (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) for its stock broking activities & is Depository participant with Central Depository Services Limited (CDSL) National Securities Depository Limited (NSDL),NERL, COMRIS and CCRL and is member of Association of Mutual Funds of India (AMFI) for distribution of financial products and Insurance Regulatory & Development Authority of India (IRDA) as Corporate Agent for insurance products. Details of associate entities of Motilal Oswal Financial Services Ltd. are available on the website at <a href="https://onlinereports.motilaloswal.com/Dormant/documents/Associate%20Details.pdf">https://onlinereports.motilaloswal.com/Dormant/documents/Associate%20Details.pdf</a>

Details of pending Enquiry Proceedings of Motilal Oswal Financial Services Limited are available on the website at https://galaxy.motilaloswal.com/ResearchAnalyst/PublishViewLitigation.aspx

MOFSL, it's associates, Research Analyst or their relatives may have any financial interest in the subject company. MOFSL and/or its associates and/or Research Analyst or their relatives may have actual beneficial ownership of 1% or more securities in the subject company at the end of the month immediately preceding the date of publication of the Research Report or date of the public appearance. MOFSL and its associate company(ies), their directors and Research Analyst and their relatives may have any other potential conflict of interests at the time of publication of the research report or at the time of public appearance, however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

In the past 12 months, MOFSL or any of its associates may have:

- a) received any compensation/other benefits from the subject company of this report
- b) managed or co-managed public offering of securities from subject company of this research report,
- c) received compensation for investment banking or merchant banking or brokerage services from subject company of this research report,
- d) received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company of this research report.
- · MOFSL and it's associates have not received any compensation or other benefits from the subject company or third party in connection with the research report.
- Subject Company may have been a client of MOFSL or its associates during twelve months preceding the date of distribution of the research report.
- Research Analyst may have served as director/officer/employee in the subject company.
- MOFSL and research analyst may engage in market making activity for the subject company.

MOFSL and its associate company(ies), and Research Analyst and their relatives from time to time may have:

- a) a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein.
- (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

Above disclosures include beneficial holdings lying in demat account of MOFSL which are opened for proprietary investments only. While calculating beneficial holdings, It does not consider demat accounts which are opened in name of MOFSL for other purposes (i.e holding client securities, collaterals, error trades etc.). MOFSL also earns DP income from clients which are not considered in above disclosures.

To enhance transparency, MOFSL has incorporated a Disclosure of Interest Statement in this document. This should, however, not be treated as endorsement of the views expressed in the report. MOFSL and / or its affiliates do and seek to do business including investment banking with companies covered in its research reports. As a result, the recipients of this report should be aware that MOFSL may have a potential conflict of interest that may affect the objectivity of this report.

#### **Terms & Conditions**

This report has been prepared by MOFSL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of MOFSL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. MOFSL will not treat recipients as customers by virtue of their receiving this report.

#### **Analyst Certification**

The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report.

Disclosure of Interest Statement	Companies where there is interest								
Analyst ownership of the stock	No								

A graph of daily closing prices of securities is available at <a href="www.nseindia.com">www.nseindia.com</a>. Research Analyst views on Subject Company may vary based on Fundamental research and Technical Research. Proprietary trading desk of MOFSL or its associates maintains arm's length distance with Research Team as all the activities are segregated from MOFSL research activity and therefore it can have an independent view with regards to subject company for which Research Team have expressed their views.

#### Regional Disclosures (outside India)

This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL & its group companies to registration or licensing requirements within such jurisdictions.

#### For Hong Kong

This report is distributed in Hong Kong by Motilal Oswal capital Markets (Hong Kong) Private Limited, a licensed corporation (CE AYY301) licensed and regulated by the Hong Kong Securities and Futures Commission (SFC) pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) "SFO". As per SEBI (Research Analyst





Regulations) 2014 Motilal Oswal Financial Services Limited (SEBI Reg No. INH000000412) has an agreement with Motilal Oswal capital Markets (Hong Kong) Private Limited for distribution of research report in Hong Kong. This report is intended for distribution only to "Professional Investors" as defined in Part I of Schedule 1 to SFO. Any investment or investment activity to which this document relates is only available to professional investor and will be engaged only with professional investors." Nothing here is an offer or solicitation of these securities, products and services in any jurisdiction where their offer or sale is not qualified or exempt from registration. The Indian Analyst(s) who compile this report is/are not located in Hong Kong & are not conducting Research Analysis in Hong Kong.

#### For U.S.

MOTILAL Oswal Financial Services Limited (MOFSL) is not a registered broker - dealer under the U.S. Securities Exchange Act of 1934, as amended (the "1934 act") and under applicable state laws in the United States. In addition MOFSL is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts), and under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by MOFSL, including the products and services described herein are not available to or intended for U.S. persons. This report is intended for distribution only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the Exchange Act and interpretations thereof by SEC (henceforth referred to as "major institutional investors"). This document must not be acted on or relied on by persons who are not major institutional investors. Any investment or investment activity to which this document relates is only available to major institutional investors and will be engaged in only with major institutional investors. In reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") and interpretations thereof by the U.S. Securities and Exchange Commission ("SEC") in order to conduct business with Institutional Investors based in the U.S., MOFSL has entered into a chaperoning agreement with a U.S. registered broker-dealer, Motilal Oswal Securities International Private Limited. ("MOSIPL"). Any business interaction pursuant to this report will have to be executed within the provisions of this chaperoning agreement.

The Research Analysts contributing to the report may not be registered /qualified as research analyst with FINRA. Such research analyst may not be associated persons of the U.S. registered broker-dealer, MOSIPL, and therefore, may not be subject to NASD rule 2711 and NYSE Rule 472 restrictions on communication with a subject company, public appearances and trading securities held by a research analyst account.

#### For Singapore

In Singapore, this report is being distributed by Motilal Oswal Capital Markets Singapore Pte Ltd ("MOCMSPL") (Co.Reg. NO. 201129401Z) which is a holder of a capital markets services license and an exempt financial adviser in Singapore,

as per the approved agreement under Paragraph 9 of Third Schedule of Securities and Futures Act (CAP 289) and Paragraph 11 of First Schedule of Financial Advisors Act (CAP 110) provided to MOCMSPL by Monetary Authority of Singapore. Persons in Singapore should contact MOCMSPL in respect of any matter arising from, or in connection with this report/publication/communication. This report is distributed solely to persons who qualify as "Institutional Investors", of which some of whom may consist of "accredited" institutional investors as defined in section 4A(1) of the Securities and Futures Act, Chapter 289 of Singapore ("the SFA"). Accordingly, if a Singapore person is not or ceases to be such an institutional investor, such Singapore Person must immediately discontinue any use of this Report and inform MOCMSPL.

#### Disclaimer:

The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent. This report and information herein is solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. Certain transactions -including those involving futures, options, another derivative products as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information and opinions contained in this document. The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. This information is subject to change without any prior notice. The Company reserves the right to make modifications and alternations to this statement as may be required from time to time without any prior approval. MOFSL, its associates, their directors and the employees may from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting the document. This report has been prepared on the basis of information that is already available in publicly accessible media or developed through analysis of MOFSL. The views expressed are those of the analyst, and the Company may or may not subscribe to all the views expressed therein. This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, copied, in whole or in part, for any purpose. This report is not directled or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction. Neither the Firm, not its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. The person accessing this information specifically agrees to exempt MOFSL or any of its affiliates or employees from, any and all responsibility/liability arising from such misuse and agrees not to hold MOFSL or any of its affiliates or employees responsible for any such misuse and further agrees to hold MOFSL or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays.

Registered Office Address: Motilal Oswal Tower, Rahimtullah Sayani Road, Opposite Parel ST Depot, Prabhadevi, Mumbai-400025; Tel No.: 022-3980 4263; www.motilaloswal.com. Correspondence Address: Palm Spring Centre, 2nd Floor, Palm Court Complex, New Link Road, Malad (West), Mumbai- 400 064. Tel No: 022 71881000. Details of Compliance Officer: Neeraj Agarwal, Email Id: na@motilaloswal.com, Contact No.:022-71881085.

Registration details of group entities.: Motilal Oswal Financial Services Ltd. (MOFSL): INZ000158836 (BSE/NSE/MCX/NCDEX); CDSL: IN-DP-16-2015; NSDL: IN-DP-NSDL-152-2000; Research Analyst: INH000000412 . AMFI: ARN .: 146822. IRDA Corporate Agent — CA0579. Motilal Oswal Financial Services Ltd. is a distributor of Mutual Funds, PMS, Fixed Deposit, Insurance, Bond, NCDs and IPO products. Customer having any query/feedback/ clarification may write to query@motilaloswal.com. In case of grievances for any of the services rendered by Motilal Oswal Financial Services Limited (MOFSL) write to grievances@motilaloswal.com, for DP to <a href="mailto:deposity.com/decapacity/deposity/deposity/decapacity/deposity/decapacity/deposity/deposity/decapacity/deposity/decapacity/deposity/d